Administração de Lactobacillus para casei 28.4 como terapia adjuvante no tratamento da periodontite: desenvolvimento in vitro de formulação probiótica usando gellan gum e ensaio clínico randomizado placebo controlado / Administration of Lactobacillus paracasei 28.4 as adjuvant therapy in the treatment of periodontitis: in vitro development of the probiotic formulation using gellan gum and placebo-controlled randomized clinical trial

A periodontite é uma doença inflamatória do periodonto associada ao acúmulo de biofilme dental, com consequente disbiose da microbiota oral e alteração da resposta imuno-inflamatória. O controle da periodontite realizado por meio do tratamento periodontal não-cirúrgico altera o ambiente subgengival e pode ser associado a terapias adjuntas. O uso de probióticos como terapia adjuvante a esse tratamento parece favorecer a modificação do biofilme bacteriano e resposta imuno-inflamatória. Entretanto, os probióticos empregados até o momento não são próprios da cavidade oral e, por isso, a busca por cepas originadas da microbiota oral tem ganhado espaço na tentativa de favorecer a aderência e colonização permanente dessas bactérias. Recentemente, a cepa de Lactobacillus paracasei 28.4 foi isolada da cavidade oral, exibindo atividades antimicrobianas promissoras sobre o controle de patógenos orais. O presente estudo teve como objetivos o desenvolvimento de uma formulação probiótica de L. paracasei 28.4 incorporado em gellan gum para uso humano, bem como a avaliação dos efeitos clínicos da administração desta formulação como adjuvante no tratamento periodontal. Para tal, o trabalho foi dividido em 2 etapas, contemplando uma etapa laboratorial (parte A), para desenvolvimento da formulação probiótica; e um ensaio clínico randomizado (parte B, n=40), envolvendo um protocolo de tratamento periodontal não cirúrgico associado à terapia adjunta probiótica ou placebo. Os resultados da parte A permitiram encontrar a melhor forma de apresentação e armazenamento da formulação de gellan gum. Na parte B, aos 3 e 6 meses de acompanhamento, os dois grupos apresentaram melhoras significativas dos parâmetros periodontais (índice de sangramento, índice gengival, profundidade de sondagem e ganho de nível de inserção) em relação ao baseline, sem diferença estatística na comparação intergrupo. Como conclusão, uma formulação probiótica segura e possível de ser aplicada na prática clínica foi obtida; no entanto, sua administração não promoveu efeitos clínicos adicionais ao tratamento de pacientes com periodontite generalizada estágios III/IV e graus B/C (AU)

Periodontitis is an inflammatory disease of the periodontium associated with the accumulation of dental biofilm, with consequent dysbiosis of the oral microbiota and alteration of the immune-inflammatory responseThe control of periodontitis carried out through non-surgical periodontal treatment alters the subgingival environment and can be associated with adjunctive therapies.The use of probiotics as an adjuvant therapy in the periodontal treatment seems to favor the modification of the bacterial biofilm and modulation of the immuneinflammatory response. However, the probiotics used so far are not specific to the oral cavity and, therefore, the search for strains originating from the oral microbiota has gained space to favor the adherence and permanent colonization of these bacteria. Recently, strain of Lactobacillus paracasei 28.4 was isolated from the oral cavity itself, showing promising antimicrobial activities in the control of oral pathogens. The present study aimed to develop and characterize a probiotic formulation of L. paracasei 28.4 incorporated into gellan gum for human use, as well as to evaluate the clinical effects of administering this formulation as an adjuvant in the treatment of periodontitis. To this end, the study was divided into 2 stages, comprising a laboratory stage (part A), for the development of the probiotic, and a randomized clinical trial (part B, n=40) contemplating a non-surgical periodontal treatment protocol associated with adjunctive probiotic therapy or placebo. The results from part A made it possible to find the best way to present and store the gellan gum formulation. In part B, at 3 and 6 months of follow-up, both groups showed significant improvements in periodontal parameters (bleeding index, gingival index, probing depth and attachment level gain) in relation to baseline, with no statistical difference in the intergroup comparison. In conclusion, a safe probiotic formulation that can be applied in clinical practice was obtained; however, its administration did not promote additional clinical effects in the treatment of patients with stage III/IV and grades B/C generalized periodontitis (AU)

Rethinking the decision-making process to treat gingival recession associated with non-carious cervical lesions

Abstract The presence of a tooth-surface defect, such as a non-carious cervical lesion (NCCL), associated with sites of gingival recession (GR) defects creates a combined soft tissue/tooth defect (CD) that requires a different treatment plan. This study aimed to critically review the literature regarding the available treatment protocols for CDs and suggest a new decision-making process. NCCLs were classified as Class A-: the cementoenamel junction (CEJ) was visible and the root surface discrepancy was < 0.5 mm (no step); Class A+: CEJ was visible and the root surface discrepancy was > 0.5 mm (with a step); Class B-: unidentifiable CEJ without a step; Class B+: unidentifiable CEJ with a step. NCCLs affecting both root and crown surfaces (Class B) lead to CEJ destruction and consequently eliminate an important landmark used before and after root coverage procedures. The depth of the root surface discrepancy is vital owing to its possible impact on soft tissue adaptation after healing, which, in turn, may influence the treatment options, namely the use of graft and/or composites to compensate for the discrepancy. Clinically, a step with horizontal depth greater than 0.5 mm should be recognized as the minimum threshold value to define this condition. Extremely deep defects tend to assume a V-shaped topography. Therefore, extremely deep V-shaped defects were classified into subclasses A+V, a V-shaped defect, and B+V, a V-shaped defect with loss of CEJ, for management considerations. The treatment options, supported by the literature, and a decision-making process to deal with each condition are presented.